Teva Pharma - TEVA Forward P/S Multiple

Teva Pharmaceutical Industries Ltd. (TEVA) - corporate logo

The shift toward innovative biosimilars and cost restructuring is currently defining the market trajectory for Teva Pharmaceutical Industries (TEVA). The company's forward P/S reflects current price momentum, where a metric value of 0.40 confirms the trend's sustainability. This is based on its global status as a generics leader and its proprietary API logistics, which transforms mass-market medications into a reliable cash cow.

TEVA (Teva) Price to Expected Revenue Ratio history from 07/04/2022 to 11/18/2026

Teva Pharmaceutical Industries (TEVA) - metric breakdowns and financial figures

- market price and analyst price targets:
Fundamental company analysis:Teva Pharmaceuticals (TEVA)
Manufactured products of Teva Pharmaceutical Industries Ltd.

The forward P/S reflects market capitalization relative to projected annual revenue, measuring investor confidence in future cash flows. By analyzing the forward P/S of a business, one can assess the extent to which the market is willing to award the company a premium for its operational efficiency and resilience. For Teva Pharmaceutical Industries (TEVA), this multiple accounts for capital expenditures on the environmental modernization of generic production facilities, which impact the final asset value.